3-O-(1-hexadecyl)cholesterol: used as liposome marker [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3080725 |
| SCHEMBL ID | 2319117 |
| MeSH ID | M0108111 |
| Synonym |
|---|
| 22032-48-0 |
| hexadecyl cholesteryl ether |
| 3-o-(1-hexadecyl)cholesterol |
| cholest-5-ene, 3-(hexadecyloxy)-, (3beta)- |
| cholesterylhexadecyl ether |
| SCHEMBL2319117 |
| cholest-5-ene, 3-(hexadecyloxy)-, (3.beta.)- |
| cholest-5-ene, 3.beta.-(hexadecyloxy)- |
| 3-(hexadecyloxy)cholest-5-ene # |
| UYLSRAUTYHWBOU-OMBIIZNESA-N |
| cholesterol hexadecyl ether |
| DTXSID00944637 |
| 3-(hexadecyloxy)cholest-5-ene |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||